Skip to main content
search

Case Studies

Sign up

Featured case study

Medicines that matter: Biohaven’s Nurtec™ drug development journey
Biohaven
Medicines that matter: Biohaven’s Nurtec™ drug development journey

Medicines that matter: Biohaven’s Nurtec™ drug development journey

In February 2020, Biohaven Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) approved Nurtec™ (Rimegepant) for the acute treatment of migraines in…

Latest case studies

Popular case studies

All case studies

Optimizing Dosing and Regulatory Outcomes in Duchenne Muscular Dystrophy (DMD) Drug Development

Certara Services, Clinical Pharmacology, Drug Development, Model Informed Drug Development, Modeling and Simulation, Case Study

Accelerating Oncology Drug FDA RTOR Submission with Project Management Services

Certara Services, Clinical Pharmacology, Clinical Trials, Drug Development, Model Informed Drug Development, Modeling and Simulation, Modeling and Simulation – PK/PD, Oncology/Hematology, Case Study

How Model-informed drug development rescue projects from a risky situation​

Certara Services, Clinical Pharmacology, Model Informed Drug Development, Modeling and Simulation, Modeling and Simulation - PBPK, Modeling and Simulation - PK/PD, Modeling and Simulation - QSP, Case Study

Enabling Personalized Therapy with PBPK Modeling for Pediatric Epilepsy

Certara Products - Simcyp, Modeling and Simulation - PBPK, Pediatrics, Case Study

Delivering DSUR Excellence for Multinational Biopharma

Certara Services, Case Study

How Certara MIDD Experts Overcame Client Regulatory Challenges

Homepage Latest, Case Study

Standardizing Real World Data in Rare Disease: ATHN’s Journey

Certara Products - Pinnacle 21, Certara Services, Homepage Latest, Case Study

Unlocking Success with Phoenix Hosted: Real-World Customer Stories

Certara Products - Phoenix, Case Study

QSP Modeling Optimizes FIH Dose Selection for Multiple Myeloma Therapy

Modeling and Simulation - QSP, Oncology/Hematology, Case Study

Quantitative systems pharmacology model of mRNA lipid nanoparticle for two programs at the preclinical to clinical transition

Modeling and Simulation - QSP, Case Study

Helping Sponsor Meet EMA Policy 0070 Requirements

Clinical Transparency & Disclosure, Regulatory, Case Study

Streamlining the Preparation of 1-Year and 2-Year PSURs

Regulatory, Case Study
Be the first to get the latest

Transforming drug development is not just our goal—it’s our obsession. If it’s yours too, then be the first to know of new insights and join us in pushing the boundaries of science.